Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

December 16, 2014

Primary Completion Date

January 15, 2019

Study Completion Date

January 27, 2023

Conditions
Germline BRCA1/2 Mutations andMetastatic Adenocarcinoma of the Pancreas
Interventions
DRUG

Olaparib

Tablet -100mg

DRUG

Olaparib

Tablet-150mg

DRUG

Placebo

Match Olaparib 100mg placebo

DRUG

Placebo

Match Olaparib 150mg placebo

Trial Locations (103)

1070

Research Site, Brussels

2020

Research Site, Antwerp

2031

Research Site, Randwick

2065

Research Site, St Leonards

2560

Research Site, Campbelltown

3000

Research Site, Leuven

6351

Research Site, Seoul

8208

Research Site, Sabadell

10016

Research Site, New York

10022

Research Site, New York

10032

Research Site, New York

10065

Research Site, New York

10967

Research Site, Berlin

11725

Research Site, Commack

13620

Research Site, Seongnam-si

15706

Research Site, Santiago de Compostela

17007

Research Site, Girona

19111

Research Site, Philadelphia

20132

Research Site, Milan

20133

Research Site, Milan

20246

Research Site, Hamburg

21287

Research Site, Baltimore

22100

Research Site, Nahariya

22291

Research Site, Hamburg

25000

Research Site, Besançon

28007

Research Site, Madrid

28034

Research Site, Madrid

28041

Research Site, Madrid

28050

Research Site, Madrid

29010

Research Site, Málaga

29609

Research Site, Brest

30625

Research Site, Hanover

31008

Research Site, Pamplona

31059

Research Site, Toulouse

33075

Research Site, Bordeaux

33136

Research Site, Miami

33486

Research Site, Boca Raton

35128

Research Site, Padua

37134

Research Site, Verona

40138

Research Site, Bologna

43126

Research Site, Parma

43210

Research Site, Columbus

44791

Research Site, Bochum

46009

Research Site, Valencia

50009

Research Site, Zaragoza

53127

Research Site, Bonn

58100

Research Site, Holon

59020

Research Site, Lille

60596

Research Site, Frankfurt am Main

60637

Research Site, Chicago

63110

Research Site, St Louis

65100

Research Site, Pescara

67065

Research Site, Strasbourg

69437

Research Site, Lyon

71013

Research Site, San Giovanni Rotondo

75014

Research Site, Paris

75674

Research Site, Paris

76100

Research Site, Rehovot

77030

Research Site, Houston

80045

Research Site, Aurora

80054

Research Site, Amiens

81675

Research Site, München

84101

Research Site, Beersheba

85234

Research Site, Gilbert

85925

Research Site, La Roche-sur-Yon

86021

Research Site, Poitiers

89081

Research Site, Ulm

92118

Research Site, Clichy

92868

Research Site, Orange

94800

Research Site, Villejuif

97422

Research Site, Schweinfurt

98104

Research Site, Seattle

3109601

Research Site, Haifa

4941492

Research Site, Petah Tikva

5265601

Research Site, Ramat Gan

6423906

Research Site, Tel Aviv

7030000

Research Site, Zefir

94305-5720

Research Site, Stanford

06510

Research Site, New Haven

02215

Research Site, Boston

N6A 4L6

Research Site, London

H3T 1E2

Research Site, Montreal

J1G 2E8

Research Site, Sherbrooke

M5G 2M9

Research Site, Toronto

06189

Research Site, Nice

D-13353

Research Site, Berlin

01307

Research Site, Dresden

04103

Research Site, Leipzig

00128

Research Site, Roma

00144

Research Site, Roma

1105 AZ

Research Site, Amsterdam

03080

Research Site, Seoul

08035

Research Site, Barcelona

08907

Research Site, L'Hospitalet de Llobregat

EH4 2XR

Research Site, Edinburgh

G12 0YN

Research Site, Glasgow

L69 3GA

Research Site, Liverpool

SE5 9RS

Research Site, London

WC1E 6AG

Research Site, London

M20 4BX

Research Site, Manchester

HA6 2RN

Research Site, Northwood

NG5 1PB

Research Site, Nottingham

SM1 2DL

Research Site, Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Myriad Genetic Laboratories, Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

AstraZeneca

INDUSTRY